Preparation of meglumine antimonate loaded albumin nanoparticles and evaluation of its anti-leishmanial activity: an in vitro assay
- 16 Downloads
Cutaneous leishmaniasis is still a health problem worldwide, especially in tropical and subtropical areas. Currently, pentavalent antimony compounds are used to treat leishmaniasis. These compounds cause various side effects in the body. Therefore, there is a need to discover new drugs with less toxicity and more therapeutic effects. In this study, we encapsulated the meglumine antimonate into the albumin as a drug carrier and evaluated the anti-leishmanial effect of the prepared nanoparticles. The precipitation method was used for this purpose by applying different concentrations of glutaraldehyde and N-(3-Dimethylaminopropyl)-N-ethyl carbodiimide hydro chloride Ethyl (DEC) and then, field emission test was performed using Scanning Electron Microscopy for evaluating the morphology and size particles. The cytotoxicity and inhibitory of drugs were evaluated on J774 macrophages and Leishmania major promastigotes, respectively. Nanodrugs prepared using glutaraldehyde (10 μl/ml) and DEC (13 mg/ml) had the smallest and largest size, respectively. The highest anti-leishmanial activity was observed in the drugs prepared with glutaraldehyde (10 μl/ml). Also this nanodrug had the lowest cytotoxicity against macrophages. Given that meglumine antimonate loaded albumin nanoparticles prepared with glutaraldehyde (10 μg/ml), can improve the anti-leishmanial effects of this old drug, it can be a good option as a drug delivery system.
KeywordsMeglumine antimonate Albumin Glutaraldehyde Encapsulation Anti-leishmanial activity
This research is a part of the project approved by the Vice-Chancellor for Research of Shiraz University of Medical Sciences at Grant Number: 95-01-01-12795. Therefore, the authors express their gratitude and thanks to the approval and financial support of this plan.
Designed and performed the study: MHM; Nanoparticles syntesis: AB, NS, MHM; Performed the cell culture, anti-leishmanial assays and data analysis: AB, SR; Participated in writing the final paper: A B, MHM.
Compliance with ethical standards
Conflict of interest
Authors declare that they have no conflict of interest.
- Benita S (2006) Microencapsulation methods and industrial applications. CRC Press, Boca RatonGoogle Scholar
- Chowdhary SJ, Chowdhary A, Kashaw S (2016) Macrophage targeting: a strategy for leishmaniasis specific delivery. Int J Pharm Pharm Sci 8:16–26Google Scholar
- Gour JK, Srivastava A, Kumar V, Bajpai S, Kumar H, Mishra M (2009) Nanomedicine and leishmaniasis: future prospects. Dig J Nanomater Biostruct 4:495–499Google Scholar
- Nejati J, Mojadam M, Hanafi Bojd AA, Keyhani A, Habibi Nodeh F (2014) An epidemiological study of cutaneous leishmaniasis in Andimeshk (2005–2010). SJIMU 21:94–101Google Scholar
- Paul M, Durand R, Boulard Y, Fusaï T, Fernandez C, Rivollet D, Deniau M, Astier A (1998) Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 5:481–490CrossRefPubMedGoogle Scholar
- Peters T (1995) All about albumin. Biochemistry, genetics and medical applications. Academic press, San DiegoGoogle Scholar
- World Health Organization (1995) WHO model prescribing information: drugs used in parasitic diseases, 2nd edn. World Health Organization, Geneva. http://www.who.int/iris/handle/10665/41765